JP2021522239A - 熱ショックタンパク質結合ペプチド組成物およびその使用方法 - Google Patents

熱ショックタンパク質結合ペプチド組成物およびその使用方法 Download PDF

Info

Publication number
JP2021522239A
JP2021522239A JP2020559376A JP2020559376A JP2021522239A JP 2021522239 A JP2021522239 A JP 2021522239A JP 2020559376 A JP2020559376 A JP 2020559376A JP 2020559376 A JP2020559376 A JP 2020559376A JP 2021522239 A JP2021522239 A JP 2021522239A
Authority
JP
Japan
Prior art keywords
amino acid
polypeptide
acid sequence
certain embodiments
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020559376A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021522239A5 (enExample
Inventor
マーク・アーサー・フィンダイス
ベンジャミン・マキシム・モーリン
ビシュヌ・ジョシー
Original Assignee
アジェナス インコーポレイテッド
アジェナス インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アジェナス インコーポレイテッド, アジェナス インコーポレイテッド filed Critical アジェナス インコーポレイテッド
Publication of JP2021522239A publication Critical patent/JP2021522239A/ja
Publication of JP2021522239A5 publication Critical patent/JP2021522239A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001111—Immunoglobulin superfamily
    • A61K39/001114—CD74, Ii, MHC class II invariant chain or MHC class II gamma chain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6901—Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5152—Tumor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6043—Heat shock proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/622—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier non-covalent binding
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2020559376A 2018-04-26 2019-04-25 熱ショックタンパク質結合ペプチド組成物およびその使用方法 Pending JP2021522239A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862663083P 2018-04-26 2018-04-26
US62/663,083 2018-04-26
US201862692009P 2018-06-29 2018-06-29
US62/692,009 2018-06-29
PCT/US2019/029112 WO2019210055A2 (en) 2018-04-26 2019-04-25 Heat shock protein-binding peptide compositions and methods of use thereof

Publications (2)

Publication Number Publication Date
JP2021522239A true JP2021522239A (ja) 2021-08-30
JP2021522239A5 JP2021522239A5 (enExample) 2022-05-10

Family

ID=67002340

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020559376A Pending JP2021522239A (ja) 2018-04-26 2019-04-25 熱ショックタンパク質結合ペプチド組成物およびその使用方法

Country Status (10)

Country Link
US (2) US11065317B2 (enExample)
EP (1) EP3784688A2 (enExample)
JP (1) JP2021522239A (enExample)
KR (1) KR20210005646A (enExample)
CN (1) CN112218883A (enExample)
AU (1) AU2019261451A1 (enExample)
CA (1) CA3096909A1 (enExample)
MA (1) MA52363A (enExample)
TW (1) TW202012430A (enExample)
WO (1) WO2019210055A2 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA52363A (fr) * 2018-04-26 2021-03-03 Agenus Inc Compositions peptidiques de liaison à une protéine de choc thermique (hsp) et leurs méthodes d'utilisation
WO2021016531A1 (en) * 2019-07-24 2021-01-28 Agenus Inc. Antigenic polypeptides and methods of use thereof
AU2023314797A1 (en) 2022-07-29 2024-12-12 Repertoire Immune Medicines, Inc. T cell epitopes associated with type 1 diabetes
WO2025072849A1 (en) 2023-09-29 2025-04-03 Repertoire Immune Medicines, Inc. Mhc-presentable peptides associated with type 1 diabetes

Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06501542A (ja) * 1990-05-11 1994-02-17 ユーロ―ディアグノスティカ　アー・ベー 診断用免疫検定法に有用なヒト乳頭腫ウイルス１，５，６，８，１１，１６，１８，３１，３３および５６の合成ペプチド類
JP2001514389A (ja) * 1997-08-27 2001-09-11 メディジン・アクチェンゲゼルシャフト・ゲゼルシャフト・フル・モレキュラバイオロジッシュ・カルジオロジエ・ウンド・オンコロジエ 皮膚試験用診断キット及びその実施方法
JP2002501722A (ja) * 1997-10-31 2002-01-22 スローン−ケターリング インスティチュート フォー キャンサー リサーチ 熱ショックタンパク質結合性コンジュゲートペプチド
JP2005505503A (ja) * 2001-05-04 2005-02-24 コミッサリア　ア　レネルジ　アトミック Ｅ６及び／又はｅ７パピローマウイルスタンパク質に由来するペプチドの混合物並びにその使用
US20060182763A1 (en) * 2005-01-31 2006-08-17 Kim Kevin H CD8 T cell epitopes in HPV 16 E6 and E7 proteins and uses thereof
JP2006523185A (ja) * 2003-02-13 2006-10-12 アンティジェニクス インコーポレーテッド 改良された熱ショックタンパク質に基づくワクチンおよび免疫療法
JP2007528838A (ja) * 2003-12-24 2007-10-18 ライデン ユニバーシティ メディカル センター 腫瘍特異的ワクチンとしての合成タンパク質
JP2010530362A (ja) * 2007-05-31 2010-09-09 アカデミシュ ジーケンハウス ライデン ハー．オー．デー．エン． ルムク 皮内ｈｐｖペプチドワクチン接種
JP2012501351A (ja) * 2008-09-02 2012-01-19 アンティジェン・エクスプレス・インコーポレーテッド ヒトパピローマウイルス／Ｉｉ−ｋｅｙのハイブリッドおよびその使用方法
JP2013504314A (ja) * 2009-09-11 2013-02-07 プロイェクト、デ、ビオメディシナ、シーマ、ソシエダッド、リミターダ Ｈｐｖにより惹起される疾患の治療用組成物
JP2016501888A (ja) * 2012-12-06 2016-01-21 キャラハン イノベーション リサーチ リミテッド コンジュゲート化合物
WO2016183486A1 (en) * 2015-05-13 2016-11-17 Agenus Inc. Vaccines for treatment and prevention of cancer
JP2016538333A (ja) * 2013-10-13 2016-12-08 ザ ボード オブ トラスティーズ オブ ザ ユニバーシティ オブ アーカンソー ヒトパピローマウイルス治療ワクチン

Family Cites Families (174)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4690915A (en) 1985-08-08 1987-09-01 The United States Of America As Represented By The Department Of Health And Human Services Adoptive immunotherapy as a treatment modality in humans
US4761470A (en) 1985-12-16 1988-08-02 Merck & Co., Inc. Immunogenic synthetic peptide capable of eliciting herpes simplex virus neutralizing antibody
US5605884A (en) 1987-10-29 1997-02-25 Rhone-Poulenc Rorer Pharmaceuticals Inc. Factor VIII formulations in high ionic strength media
US4877608A (en) 1987-11-09 1989-10-31 Rorer Pharmaceutical Corporation Pharmaceutical plasma protein formulations in low ionic strength media
US5137819A (en) 1988-07-08 1992-08-11 University Of British Columbia Cellulose binding fusion proteins for immobilization and purification of polypeptides
US5232833A (en) 1988-09-14 1993-08-03 Stressgen Biotechnologies Corporation Accumulation of heat shock proteins for evaluating biological damage due to chronic exposure of an organism to sublethal levels of pollutants
GB8915019D0 (en) 1989-06-30 1989-08-23 Matthews Ruth C Medicaments
DE4001451A1 (de) 1990-01-19 1991-08-01 Octapharma Ag Stabile injizierbare loesungen von faktor viii und faktor ix
US5348945A (en) 1990-04-06 1994-09-20 Wake Forest University Method of treatment with hsp70
US5188964A (en) 1990-04-12 1993-02-23 Board Of Regents, The University Of Texas System Method and kit for the prognostication of breast cancer patient via heat shock/stress protein determination
US6037135A (en) 1992-08-07 2000-03-14 Epimmune Inc. Methods for making HLA binding peptides and their uses
CA2118015A1 (en) 1992-04-14 1993-10-28 Jeffrey R. Marks Method of detecting tumors containing complexes of p53 and hsp70
CA2124690C (en) 1992-10-02 2007-09-11 Thomas Osterberg Composition comprising coagulation factor viii formulation, process for its preparation and use of a surfactant as stabilizer
US5496934A (en) 1993-04-14 1996-03-05 Yissum Research Development Company Of The Hebrew University Of Jerusalem Nucleic acids encoding a cellulose binding domain
US5750119A (en) 1994-01-13 1998-05-12 Mount Sinai School Of Medicine Of The City University Of New York Immunotherapeutic stress protein-peptide complexes against cancer
US5997873A (en) 1994-01-13 1999-12-07 Mount Sinai School Of Medicine Of The City University Of New York Method of preparation of heat shock protein 70-peptide complexes
US5961979A (en) 1994-03-16 1999-10-05 Mount Sinai School Of Medicine Of The City University Of New York Stress protein-peptide complexes as prophylactic and therapeutic vaccines against intracellular pathogens
GB9501040D0 (en) 1995-01-19 1995-03-08 Quadrant Holdings Cambridge Dried composition
IL123218A0 (en) 1995-08-18 1998-09-24 Sloan Kettering Inst Cancer Heat shock protein-based vaccines and immunotherapies
US5985270A (en) 1995-09-13 1999-11-16 Fordham University Adoptive immunotherapy using macrophages sensitized with heat shock protein-epitope complexes
JPH11513369A (ja) 1995-09-13 1999-11-16 フォーダム ユニバーシティー 熱ショックタンパク質を用いる治療及び予防方法
US5837251A (en) 1995-09-13 1998-11-17 Fordham University Compositions and methods using complexes of heat shock proteins and antigenic molecules for the treatment and prevention of neoplastic diseases
US5935576A (en) 1995-09-13 1999-08-10 Fordham University Compositions and methods for the treatment and prevention of neoplastic diseases using heat shock proteins complexed with exogenous antigens
DE19602985A1 (de) 1996-01-27 1997-07-31 Max Delbrueck Centrum Tumorzellimpfstoff für die Immuntheraphie von malignen Tumoren
RS50101B (sr) 1996-02-24 2009-01-22 Boehringer Ingelheim International Gmbh., Farmaceutski preparati za imunomodulaciju
US5763401A (en) 1996-07-12 1998-06-09 Bayer Corporation Stabilized albumin-free recombinant factor VIII preparation having a low sugar content
WO1998014207A1 (en) 1996-10-01 1998-04-09 Dana-Farber Cancer Institute Immunological therapy for cancer
US6231859B1 (en) 1996-12-02 2001-05-15 Aquila Biopharmaceuticals, Inc. Saponin adjuvant compositions
US5830464A (en) 1997-02-07 1998-11-03 Fordham University Compositions and methods for the treatment and growth inhibition of cancer using heat shock/stress protein-peptide complexes in combination with adoptive immunotherapy
US6017540A (en) 1997-02-07 2000-01-25 Fordham University Prevention and treatment of primary and metastatic neoplastic diseases and infectious diseases with heat shock/stress protein-peptide complexes
ES2265165T3 (es) 1997-07-10 2007-02-01 Mannkind Corporation Dispositivo para inducir una respuesta ltc.
US6977074B2 (en) 1997-07-10 2005-12-20 Mannkind Corporation Method of inducing a CTL response
EP0893507A1 (en) 1997-07-25 1999-01-27 Institut Gustave Roussy Use of MHC class II ligands (CD4 and LAG-3) as adjuvant for vaccination and of LAG-3 in cancer treatment
CA2302522C (en) 1997-08-29 2010-08-17 Antigenics Llc Compositions comprising the adjuvant qs-21 and polysorbate or cyclodextrin as excipient
EP1030819A4 (en) 1997-09-30 2001-11-21 Cel Sci Corp CONJUGATED IMMUNOGENIC POLYPEPTIDE FOR THE TREATMENT OF HERPES SIMPLEX VIRUS
US6007821A (en) 1997-10-16 1999-12-28 Fordham University Method and compositions for the treatment of autoimmune disease using heat shock proteins
US5948646A (en) 1997-12-11 1999-09-07 Fordham University Methods for preparation of vaccines against cancer comprising heat shock protein-peptide complexes
JP2002506633A (ja) 1998-03-20 2002-03-05 ジェンザイム・コーポレーション Ｔ細胞応答を誘発するための遺伝子に基づくワクチンの組成物および使用法
NO315238B1 (no) 1998-05-08 2003-08-04 Gemvax As Peptider som stammer fra leserammeforskyvingsmutasjoner i TBF<beta>II- eller BAX-genet, og farmasöytiske sammensetninger inneholdende disse,nukleinsyresekvenser som koder for slike peptider, plasmider og virusvektoreromfattende slikenukleinsy
SI1077722T1 (sl) 1998-05-22 2007-02-28 Ottawa Health Research Inst Metode in produkti za induciranje sluznicne imunosti
PT1104306E (pt) 1998-08-10 2006-05-31 Antigenics Inc Composicoes de cpg e adjuvantes de saponina e seus metodos
SK4272001A3 (en) 1998-10-05 2003-02-04 Pharmexa As Methods for therapeutic vaccination
US6451316B1 (en) 1998-10-05 2002-09-17 University Of Conneticut Health Center Methods for generating antigen-reactive T cells in vitro
US6475490B1 (en) 1998-10-19 2002-11-05 Fordham University Compositions and methods for promoting tissue repair using heat shock proteins
US7851591B1 (en) 1998-10-29 2010-12-14 Dana Farber Cancer Institute, Inc. Cancer immunotherapy and diagnosis using universal tumor associated antigens, including hTERT
PL354286A1 (en) 1999-08-23 2003-12-29 Dana-Farber Cancer Institutedana-Farber Cancer Institute Pd-1, a receptor for b7-4, and uses therefor
DK1234031T3 (en) 1999-11-30 2017-07-03 Mayo Foundation B7-H1, AN UNKNOWN IMMUNE REGULATORY MOLECULE
US20010034042A1 (en) 2000-01-20 2001-10-25 Srivastava Pramod K. Complexes of peptide-binding fragments of heat shock proteins and their use as immunotherapeutic agents
GB0004547D0 (en) 2000-02-23 2000-04-19 Immunobiology Ltd Screening method for novel vaccine candidates and compositions obtained thereby
US20020044948A1 (en) 2000-03-15 2002-04-18 Samir Khleif Methods and compositions for co-stimulation of immunological responses to peptide antigens
CA2406472A1 (en) 2000-04-17 2001-10-25 James E. Rothman Javelinization of protein antigens to heat shock proteins
EP1286693A4 (en) 2000-06-02 2005-07-13 Univ Connecticut Health Ct COMPLEXES OF ALPHA (2) MACROGLOBULIN AND ANTIGENIC MOLECULES FOR USE IN IMMUNOTHERAPY
US7186515B1 (en) 2000-06-02 2007-03-06 University Of Connecticut Health Center Alpha(2) macroglobulin receptor as a heat shock protein receptor and uses thereof
US6989146B2 (en) * 2000-08-09 2006-01-24 The Regents Of The University Of California Stress proteins and peptides and methods of use thereof
US7132109B1 (en) 2000-10-20 2006-11-07 University Of Connecticut Health Center Using heat shock proteins to increase immune response
CN1635896A (zh) 2001-08-20 2005-07-06 康涅狄格大学健康中心 包含用于治疗癌症及感染性疾病的热休克蛋白或α2－巨球蛋白的组合物制备方法
CA2466279A1 (en) 2001-11-13 2003-05-22 Dana-Farber Cancer Institute, Inc. Agents that modulate immune cell activation and methods of use thereof
US20040071656A1 (en) 2001-12-26 2004-04-15 Felix Wieland Modulation of heat-shock-protein-based immunotherapies
KR20040105736A (ko) 2002-02-28 2004-12-16 안티제닉스 아이엔씨 스트레스 단백질의 올리고머화에 기초한 방법 및 산물
US6984389B2 (en) 2002-04-25 2006-01-10 University Of Connecticut Health Center Using heat shock proteins to improve the therapeutic benefit of a non-vaccine treatment modality
WO2003090686A2 (en) 2002-04-25 2003-11-06 University Of Connecticut Health Center Using heat shock proteins to improve the therapeutic benefit of a non-vaccine treatment modality
JP2005533015A (ja) 2002-05-02 2005-11-04 ユニバーシティー オブ コネティカット ヘルス センター 抗体療法の有効性を増強するための熱ショックタンパク質の使用
IL149820A0 (en) 2002-05-23 2002-11-10 Curetech Ltd Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency
US20050221350A1 (en) 2002-05-29 2005-10-06 Toni Weinschenk Method for identifying immunoreactive peptides
AU2003281200A1 (en) 2002-07-03 2004-01-23 Tasuku Honjo Immunopotentiating compositions
WO2004007527A2 (en) * 2002-07-11 2004-01-22 Incyte Corporation Secreted proteins
EP1576124A2 (en) 2002-10-07 2005-09-21 Antigenics Inc. Heat shock protein binding fragments of cd91, and uses thereof
CN101899114A (zh) 2002-12-23 2010-12-01 惠氏公司 抗pd-1抗体及其用途
WO2004074454A2 (en) 2003-02-20 2004-09-02 University Of Connecticut Health Center Methods and compositions for the treatment of cancer and infectious disease using alpha (2) macroglobulin-antigenic molecule complexes
CA2514500A1 (en) 2003-02-20 2004-09-10 University Of Connecticut Health Center Methods for using compositions comprising heat shock proteins or alpha-2-macroglobulin in the treatment of cancer and infectious disease
CN1780850A (zh) * 2003-02-28 2006-05-31 抗基因公司 凝集素在促进糖蛋白和抗原分子的低聚反应中的用途
EP1617804A4 (en) 2003-04-11 2007-07-25 Antigenics Inc IMPROVED VACCINE BASED ON HEAT SHOCK PROTEINS AND IMMUNOTHERAPIES
US7309491B2 (en) 2003-04-11 2007-12-18 Antigenics Inc. Heat shock protein-based vaccines and immunotherapies
CA2538794C (en) 2003-09-12 2016-04-19 Antigenics, Inc. Vaccine for treatment and prevention of herpes simplex virus infection
WO2005076009A2 (en) 2004-01-28 2005-08-18 Immatics Biotechnologies Gmbh Method for identifying and quantifying of tumour-associated peptides
US20090304679A1 (en) 2004-05-27 2009-12-10 Weidanz Jon A Antibodies as T cell receptor mimics, methods of production and uses thereof
WO2006105255A2 (en) 2005-03-29 2006-10-05 The Board Of Trustees Of The University Of Illinois Cancer vaccines and therapeutic methods
DK2439273T3 (da) 2005-05-09 2019-06-03 Ono Pharmaceutical Co Humane monoklonale antistoffer til programmeret død-1(pd-1) og fremgangsmåder til behandling af cancer ved anvendelse af anti-pd-1- antistoffer alene eller i kombination med andre immunterapeutika
WO2006120038A2 (en) 2005-05-09 2006-11-16 Vaxon Biotech Use of native peptides and their optimized derivatives for vaccination
PT1907424E (pt) 2005-07-01 2015-10-09 Squibb & Sons Llc Anticorpos monoclonais humanos para o ligando 1 de morte programada (pd-l1)
US9732131B2 (en) 2006-02-27 2017-08-15 Calviri, Inc. Identification and use of novopeptides for the treatment of cancer
JP2009532664A (ja) 2006-02-27 2009-09-10 アリゾナ・ボード・オブ・リージェンツ・フォー・アンド・オン・ビハーフ・オブ・アリゾナ・ステイト・ユニバーシティ 癌の治療のためのノボペプチドの同定および使用
WO2008027800A2 (en) 2006-08-29 2008-03-06 Temple University - Of The Commonwealth System Of Higher Education Method for enhancing the efficacy of antigen specific tumor immunotherapy
AT504160A1 (de) 2006-09-11 2008-03-15 Ralf Dr Kircheis Verwendung einer mehrkomponenten-tumorvakzine
WO2008035350A1 (en) 2006-09-21 2008-03-27 Vaxil Biotherapeutics Ltd. Antigen specific multi epitope vaccines
US7998486B2 (en) 2006-10-25 2011-08-16 Newlink Genetics Corporation Enhanced immunogenicity of tumor associated antigens by addition of alphaGal epitopes
DE102006060824B4 (de) 2006-12-21 2011-06-01 Johannes-Gutenberg-Universität Mainz Nachweis von individuellen T-Zell-Reaktionsmustern gegen Tumor-assoziierte Antigene (TAA) in Tumorpatienten als Basis für die individuelle therapeutische Vakzinierung von Patienten
CN103736086A (zh) 2007-02-15 2014-04-23 曼康公司 用于增强t细胞应答的方法
US8140270B2 (en) 2007-03-22 2012-03-20 National Center For Genome Resources Methods and systems for medical sequencing analysis
BR122017025062B8 (pt) 2007-06-18 2021-07-27 Merck Sharp & Dohme anticorpo monoclonal ou fragmento de anticorpo para o receptor de morte programada humano pd-1, polinucleotídeo e composição compreendendo o referido anticorpo ou fragmento
US8926961B2 (en) * 2007-10-03 2015-01-06 Board Of Trustees Of The University Of Arkansas HPV E6 protein T cell epitopes and uses thereof
CN101970499B (zh) 2008-02-11 2014-12-31 治疗科技公司 用于肿瘤治疗的单克隆抗体
EP2626081B1 (en) 2008-02-14 2017-03-22 Life Sciences Research Partners VZW Immunogenic control of tumours and tumour cells
EP2262837A4 (en) 2008-03-12 2011-04-06 Merck Sharp & Dohme PD-1 BINDING PROTEINS
EP2113253B1 (en) 2008-04-30 2010-03-31 Immatics Biotechnologies GmbH Novel formulations of tumour-associated peptides binding to human leukocyte antigen (HLA) class I or II molecules for vaccines
JP2009273377A (ja) 2008-05-12 2009-11-26 Igaku Seibutsugaku Kenkyusho:Kk Ｍｈｃクラスｉ分子と結合し癌細胞の表面に表出されるペプチド候補の選択方法
JP5465720B2 (ja) 2008-07-08 2014-04-09 インサイト・コーポレイション インドールアミン２，３−ジオキシゲナーゼの阻害剤としての１，２，５−オキサジアゾール
AU2009288730B2 (en) 2008-08-25 2013-06-20 Amplimmune, Inc. Compositions of PD-1 antagonists and methods of use
AU2009290544B2 (en) 2008-09-12 2015-07-16 Oxford University Innovation Limited PD-1 specific antibodies and uses thereof
US8552154B2 (en) 2008-09-26 2013-10-08 Emory University Anti-PD-L1 antibodies and uses therefor
EP3255060A1 (en) 2008-12-09 2017-12-13 F. Hoffmann-La Roche AG Anti-pd-l1 antibodies and their use to enhance t-cell function
RU2011144575A (ru) 2009-04-03 2013-05-10 Эйдженус Инк. Способы получения и применения мультишаперон-антигенных комплексов
ES2533228T3 (es) 2009-06-09 2015-04-08 Vaxon Biotech Identificación, optimización y uso de epítopos compartidos de HLA-B*0702 para inmunoterapia
PL2504364T3 (pl) 2009-11-24 2017-12-29 Medimmune Limited Ukierunkowane środki wiążące przeciwko B7-H1
US20130202623A1 (en) 2010-02-16 2013-08-08 Nicolas Chomont Pd-1 modulation and uses thereof for modulating hiv replication
EP2545078A1 (en) 2010-03-11 2013-01-16 UCB Pharma, S.A. Pd-1 antibody
GB201006360D0 (en) 2010-04-16 2010-06-02 Immatics Biotechnologies Gmbh Method for differentially quantifying naturally processed HLA-restricted peptides for cancer, autoimmune and infectious diseases immunotherapy development
EP2569633B1 (en) 2010-05-14 2016-02-10 The General Hospital Corporation Compositions and methods of identifying tumor specific neoantigens
AU2011255463A1 (en) 2010-05-21 2012-11-01 University Of Miami Cancer treatment
EP2576614A4 (en) 2010-05-24 2013-11-13 Phosimmune Inc CLASS I-MHC PHOSPHOPEPTIDES FOR CANCER IMMUNOTHERAPY AND DIAGNOSIS
KR102042253B1 (ko) 2010-05-25 2019-11-07 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 Ｂａｍｂａｍ：고처리율 서열분석 데이터의 병렬 비교 분석
US9646134B2 (en) 2010-05-25 2017-05-09 The Regents Of The University Of California Bambam: parallel comparative analysis of high-throughput sequencing data
FR2960542B1 (fr) * 2010-05-27 2012-08-17 Esther Suzy Arlette Fellous Peptide en tant que medicament, en particulier pour le traitement du cancer
US10434197B2 (en) 2010-07-23 2019-10-08 University Of Delaware Tetrazine-trans-cyclooctene ligation for the rapid construction of radionuclide labeled probes
KR102759126B1 (ko) 2010-12-30 2025-01-24 파운데이션 메디신 인코포레이티드 종양 샘플의 다유전자 분석의 최적화
BR112013023978B1 (pt) 2011-03-21 2021-09-08 Atlantic Cancer Research Institute Polipeptídeo com afinidade por proteínas de choque térmico e seu uso em diagnóstico de doença infecciosa, produção de resposta imune e tratamento de câncer, bem como ácido nucleico, composição e método de fracionamento de substância para pesquisa ou análise clínica de amostra biológica
WO2012129520A1 (en) 2011-03-24 2012-09-27 Texas Tech University System Tcr mimic antibodies as vascular targeting tools
MX2013011363A (es) 2011-04-01 2014-04-25 Sloan Kettering Inst Cancer Anticuerpos para peptidos citosolicos.
JP6072771B2 (ja) 2011-04-20 2017-02-01 メディミューン，エルエルシー Ｂ７−ｈ１およびｐｄ−１に結合する抗体およびその他の分子
WO2012159643A1 (en) 2011-05-24 2012-11-29 Biontech Ag Individualized vaccines for cancer
PL3892295T3 (pl) 2011-05-24 2023-07-24 BioNTech SE Zindywidualizowane szczepionki przeciwnowotworowe
CA2840018C (en) 2011-07-24 2019-07-16 Curetech Ltd. Variants of humanized immunomodulatory monoclonal antibodies
AU2012302778B2 (en) 2011-08-31 2016-11-24 Mie University Vaccine preparation for cancer treatment
US8920075B2 (en) 2011-09-01 2014-12-30 Halo Maritime Defense Systems, Inc. Marine barrier and gate
KR101764096B1 (ko) 2011-11-28 2017-08-02 메르크 파텐트 게엠베하 항-ｐｄ-ｌ1 항체 및 그의 용도
WO2013158611A1 (en) 2012-04-16 2013-10-24 Agenus Inc. Methods and compositions for the treatment of glioblastomas
CA2886218A1 (en) 2012-05-25 2013-11-28 Phosimmune, Inc. Identification of mhc class i phospho-peptide antigens from breast cancer utilizing shla technology and complementary enrichment strategies
MX2014014199A (es) 2012-05-25 2015-02-12 Bayer Healthcare Llc Sistema y procedimiento de prediccion de la inmunogenicidad de un peptido.
KR20220084444A (ko) 2012-05-31 2022-06-21 소렌토 쎄라퓨틱스, 인코포레이티드 Pd-l1에 결합하는 항원 결합 단백질
WO2014012051A1 (en) 2012-07-12 2014-01-16 Persimmune, Inc. Personalized cancer vaccines and adoptive immune cell therapies
CN111499755A (zh) 2012-08-03 2020-08-07 丹娜法伯癌症研究院 抗-pd-l1和pd-l2双结合抗体单一试剂及其使用方法
GB201214007D0 (en) 2012-08-07 2012-09-19 Scancell Ltd Anti-tumour immune responses to modified self-epitopes
EP2891099A4 (en) 2012-08-28 2016-04-20 Broad Inst Inc DETECTION OF DATA SEQUENCING AND BENCHMARKING VARIANTS
US9561266B2 (en) 2012-08-31 2017-02-07 University Of Virginia Patent Foundation Target peptides for immunotherapy and diagnostics
WO2014039675A2 (en) 2012-09-05 2014-03-13 University Of Virginia Patent Foundation Target peptides for colorectal cancer therapy and diagnostics
LT2901341T (lt) 2012-09-28 2019-09-25 The University Of Connecticut Protekcinių vėžio epitopų identifikavimas, skirtas vėžio gydymui
BR112015007672A2 (pt) 2012-10-04 2017-08-08 Dana Farber Cancer Inst Inc anticorpos anti-pd-l1 monoclonais humanos e métodos de uso
EP3417874B1 (en) 2012-11-28 2024-09-11 BioNTech SE Individualized vaccines for cancer
HK1216153A1 (zh) 2012-12-13 2016-10-21 University Of Virginia Patent Foundation 用於卵巢癌治疗和诊断的靶向肽
AR093984A1 (es) 2012-12-21 2015-07-01 Merck Sharp & Dohme Anticuerpos que se unen a ligando 1 de muerte programada (pd-l1) humano
WO2014160902A1 (en) 2013-03-27 2014-10-02 Fred Hutchinson Cancer Research Center Directed immune stimulation
EP2983702A2 (en) 2013-04-07 2016-02-17 The Broad Institute, Inc. Compositions and methods for personalized neoplasia vaccines
SMT202100065T1 (it) 2013-05-02 2021-03-15 Anaptysbio Inc Anticorpi diretti contro la proteina della morte programmata (pd-1)
WO2014180490A1 (en) 2013-05-10 2014-11-13 Biontech Ag Predicting immunogenicity of t cell epitopes
WO2014194302A2 (en) 2013-05-31 2014-12-04 Sorrento Therapeutics, Inc. Antigen binding proteins that bind pd-1
WO2014200910A2 (en) 2013-06-10 2014-12-18 Iogenetics, Llc Bioinformatic processes for determination of peptide binding
US20160145355A1 (en) 2013-06-24 2016-05-26 Biomed Valley Discoveries, Inc. Bispecific antibodies
CN104250302B (zh) 2013-06-26 2017-11-14 上海君实生物医药科技股份有限公司 抗pd‑1抗体及其应用
US20160186260A1 (en) 2013-07-26 2016-06-30 Sequenta, Llc Cancer vaccination with antigen evolution
WO2015014375A1 (en) 2013-07-30 2015-02-05 Biontech Ag Tumor antigens for determining cancer therapy
US10077305B2 (en) 2013-09-10 2018-09-18 Medimmune Limited Antibodies against PD-1 and uses thereof
CN112552401B (zh) 2013-09-13 2023-08-25 广州百济神州生物制药有限公司 抗pd1抗体及其作为治疗剂与诊断剂的用途
CN104558177B (zh) 2013-10-25 2020-02-18 苏州思坦维生物技术股份有限公司 拮抗抑制程序性死亡受体pd-1与其配体结合的单克隆抗体及其编码序列与用途
EP3060581A4 (en) 2013-10-25 2017-06-07 Dana-Farber Cancer Institute, Inc. Anti-pd-l1 monoclonal antibodies and fragments thereof
US20160310584A1 (en) 2013-12-06 2016-10-27 The Broad Institute Inc. Formulations for neoplasia vaccines
SG10201804945WA (en) 2013-12-12 2018-07-30 Shanghai hengrui pharmaceutical co ltd Pd-1 antibody, antigen-binding fragment thereof, and medical application thereof
KR20230076867A (ko) 2013-12-20 2023-05-31 더 브로드 인스티튜트, 인코퍼레이티드 신생항원 백신과의 병용 요법
EP3090066A4 (en) 2014-01-02 2017-08-30 Memorial Sloan Kettering Cancer Center Determinants of cancer response to immunotherapy
PL3094351T3 (pl) 2014-01-15 2022-06-27 Kadmon Corporation, Llc Środki immunomodulujące
TWI680138B (zh) 2014-01-23 2019-12-21 美商再生元醫藥公司 抗ｐｄ-ｌ１之人類抗體
BR112016014952A2 (pt) 2014-02-10 2017-09-19 Merck Patent Gmbh Inibição direcionada de tgfbeta
US20150315247A1 (en) 2014-05-04 2015-11-05 David Charles Binder High-affinity peptide-based anticancer vaccination to overcome tumor resistance to immunostimulatory antibodies and to identify TCRs that can be used successfully in adoptive T cell therapy
GB201408255D0 (en) 2014-05-09 2014-06-25 Immatics Biotechnologies Gmbh Novel immunotherapy against several tumours of the blood, such as acute myeloid leukemia (AML)
JP6666905B2 (ja) 2014-05-29 2020-03-18 スプリング バイオサイエンス コーポレーション Ｐｄ−ｌ１抗体及びその使用
WO2015195163A1 (en) 2014-06-20 2015-12-23 R-Pharm Overseas, Inc. Pd-l1 antagonist fully human antibody
TWI693232B (zh) 2014-06-26 2020-05-11 美商宏觀基因股份有限公司 與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法
CN106604742B (zh) 2014-07-03 2019-01-11 百济神州有限公司 抗pd-l1抗体及其作为治疗剂及诊断剂的用途
CN105330740B (zh) 2014-07-30 2018-08-17 珠海市丽珠单抗生物技术有限公司 抗pd-1抗体及其应用
KR102357893B1 (ko) 2014-08-05 2022-02-04 맵퀘스트 에스아 Pd-1 에 결합하는 면역학적 시약
DK3186283T3 (da) 2014-08-29 2020-03-02 Hoffmann La Roche Kombinationsbehandling med tumormålrettede IL-2- immuncytokinervarianter og antistoffer mod humant PD-L1
EP3191121B1 (en) 2014-09-10 2020-05-27 The University of Connecticut Identification of immunologically protective neo-epitopes for the treatment of cancers
WO2016040900A1 (en) 2014-09-14 2016-03-17 Washington University Personalized cancer vaccines and methods therefor
WO2017088080A1 (es) 2015-11-25 2017-06-01 Natural Response S.A. Método para la obtención de saponinas a partir de plantas
MA52363A (fr) * 2018-04-26 2021-03-03 Agenus Inc Compositions peptidiques de liaison à une protéine de choc thermique (hsp) et leurs méthodes d'utilisation

Patent Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06501542A (ja) * 1990-05-11 1994-02-17 ユーロ―ディアグノスティカ　アー・ベー 診断用免疫検定法に有用なヒト乳頭腫ウイルス１，５，６，８，１１，１６，１８，３１，３３および５６の合成ペプチド類
JP2001514389A (ja) * 1997-08-27 2001-09-11 メディジン・アクチェンゲゼルシャフト・ゲゼルシャフト・フル・モレキュラバイオロジッシュ・カルジオロジエ・ウンド・オンコロジエ 皮膚試験用診断キット及びその実施方法
JP2002501722A (ja) * 1997-10-31 2002-01-22 スローン−ケターリング インスティチュート フォー キャンサー リサーチ 熱ショックタンパク質結合性コンジュゲートペプチド
JP2005505503A (ja) * 2001-05-04 2005-02-24 コミッサリア　ア　レネルジ　アトミック Ｅ６及び／又はｅ７パピローマウイルスタンパク質に由来するペプチドの混合物並びにその使用
JP2006523185A (ja) * 2003-02-13 2006-10-12 アンティジェニクス インコーポレーテッド 改良された熱ショックタンパク質に基づくワクチンおよび免疫療法
JP2007528838A (ja) * 2003-12-24 2007-10-18 ライデン ユニバーシティ メディカル センター 腫瘍特異的ワクチンとしての合成タンパク質
US20060182763A1 (en) * 2005-01-31 2006-08-17 Kim Kevin H CD8 T cell epitopes in HPV 16 E6 and E7 proteins and uses thereof
JP2010530362A (ja) * 2007-05-31 2010-09-09 アカデミシュ ジーケンハウス ライデン ハー．オー．デー．エン． ルムク 皮内ｈｐｖペプチドワクチン接種
JP2012501351A (ja) * 2008-09-02 2012-01-19 アンティジェン・エクスプレス・インコーポレーテッド ヒトパピローマウイルス／Ｉｉ−ｋｅｙのハイブリッドおよびその使用方法
JP2013504314A (ja) * 2009-09-11 2013-02-07 プロイェクト、デ、ビオメディシナ、シーマ、ソシエダッド、リミターダ Ｈｐｖにより惹起される疾患の治療用組成物
JP2016501888A (ja) * 2012-12-06 2016-01-21 キャラハン イノベーション リサーチ リミテッド コンジュゲート化合物
JP2016538333A (ja) * 2013-10-13 2016-12-08 ザ ボード オブ トラスティーズ オブ ザ ユニバーシティ オブ アーカンソー ヒトパピローマウイルス治療ワクチン
WO2016183486A1 (en) * 2015-05-13 2016-11-17 Agenus Inc. Vaccines for treatment and prevention of cancer

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BARTKOWIAK T. ET AL., PROC NATL ACAD SCI U S A, vol. 112, JPN6023009991, 2015, pages 5290 - 5299, ISSN: 0005010777 *
MANURI PR. ET AL., VACCINE, vol. 25, JPN6023009990, 2007, pages 3302 - 3310, ISSN: 0005010776 *
水上 修作: "熱ショックタンパク質と抗腫瘍免疫", 岡山医学会雑誌, vol. 124, JPN6023009992, 2012, pages 175 - 177, ISSN: 0005010778 *

Also Published As

Publication number Publication date
TW202012430A (zh) 2020-04-01
MA52363A (fr) 2021-03-03
US20200000905A1 (en) 2020-01-02
EP3784688A2 (en) 2021-03-03
US11065317B2 (en) 2021-07-20
WO2019210055A3 (en) 2019-12-19
WO2019210055A2 (en) 2019-10-31
AU2019261451A2 (en) 2020-12-10
US20220008527A1 (en) 2022-01-13
CA3096909A1 (en) 2019-10-31
AU2019261451A1 (en) 2020-12-03
KR20210005646A (ko) 2021-01-14
CN112218883A (zh) 2021-01-12

Similar Documents

Publication Publication Date Title
JP6925980B2 (ja) がんの処置および予防のためのワクチン
US20220008527A1 (en) Heat Shock Protein-Binding Peptide Compositions And Methods Of Use Thereof
JP5883804B2 (ja) 単純ヘルペスウイルス感染の治療および予防用ワクチン
JP7346291B2 (ja) 癌を治療するための細胞透過性ペプチド、マルチエピトープ、及びｔｌｒペプチドアゴニストを含む融合体
CA2393730A1 (en) Hla class i a2 tumor associated antigen peptides and vaccine compositions
WO2019018796A1 (en) VACCINE EPITOPES AGAINST HERPES SIMPLEX VIRUS RECOGNIZED SPECIFICALLY BY MEMORY T LYMPHOCYTES RESIDING IN FABRICS
EA025831B1 (ru) Композиции из hyr1-производных и способы лечения ими
US7420037B2 (en) Heat shock protein-based vaccines and immunotherapies
CA3163485A1 (en) Teipp peptide variant and uses thereof
US20220275049A1 (en) Antigenic polypeptides and methods of use thereof
US20220257733A1 (en) Antigenic polypeptides and methods of use thereof
US20140147490A1 (en) Hla class i a2 tumor associated antigen peptides and vaccine compositions
US20220362361A1 (en) Compositions and methods for producing enhanced immune responses and rapid antibody production
Cazorla et al. Redirection of the immune response to the functional catalytic domain of cruzipain improves protective immunity against Trypanosoma cruzi infection
MHC Mycobacterium tuberculosis Heat Shock

Legal Events

Date Code Title Description
A529 Written submission of copy of amendment under article 34 pct

Free format text: JAPANESE INTERMEDIATE CODE: A529

Effective date: 20201221

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220422

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220422

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230308

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230313

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20231016